Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1743102 10.3389/fphar.2025.1743102 Review Targeting Hippo-YAP/TAZ signaling pathway: an updated review demonstrating the therapeutic potential of key plant derived anticancer compounds Elsori et al. 10.3389/fphar.2025.1743102 Elsori Deena 1 Conceptualization Formal Analysis Methodology Visualization Writing - original draft Writing - review and editing Pandey Pratibha 2 Conceptualization Formal Analysis Supervision Validation Writing - original draft Writing - review and editing Alshaikh Kholoud 3 Formal Analysis Methodology Project administration Visualization Writing - review and editing Alkhathami Ali G. 4 * Conceptualization Supervision Validation Visualization Writing - review and editing Saeed Mohd 5 Formal Analysis Supervision Validation Writing - review and editing Singh Ajay 6 Investigation Methodology Validation Writing - review and editing Khan Fahad 7 * Conceptualization Supervision Validation Writing - original draft Writing - review and editing Faculty of Resilience, Rabdan Academy, Abu Dhabi, United Arab Emirates Centre for Research Impact and Outcome, Chitkara University, Rajpura, Punjab, India Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia Department of Biology, College of Science, University of Hail, Hail, Saudi Arabia School of Applied and Life Sciences, Uttaranchal University, Dehradun, India Department of Community Medicine, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India Correspondence: Ali G. Alkhathami, agaithan@kku.edu.sa; Fahad Khan, fahadintegralian@gmail.com 21 01 2026 2025 16 1743102 10 11 2025 20 12 2025 29 12 2025 Copyright © 2026 Elsori, Pandey, Alshaikh, Alkhathami, Saeed, Singh and Khan. 2026 Elsori, Pandey, Alshaikh, Alkhathami, Saeed, Singh and Khan https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A signaling mechanism that has persisted through evolution, the Hippo pathway is involved in the development and progression of many different types of cancer. Specifically, the complex comprising YAP, TAZ and TEAD is a crucial component of the Hippo signaling, which governs cell growth and stem cell activity. The upregulation of YAP/TAZ/TEAD complex has been demonstrated to result in cellular proliferation, transformation, and ultimately, carcinogenesis. Consequently, it has been shown that Hippo signaling is a prospective target for cancer treatment and prevention. Numerous natural compounds have been identified as inhibitors of the Hippo signaling pathway that downregulate YAP and TAZ in various ways. In several cancer models, plant-derived natural compound inhibitors have been shown to function as both preventative and therapeutic agents. This study examined the modulatory effects of extensively investigated antitumor natural products on the Hippo signaling system and highlights new advancements in Hippo signaling inhibitors that enhance the efficacy of standard cancer therapies. This article offers extensive insight into plant derived anticancer compounds mainly apigenin, curcumin, EGCG, resveratrol, homoharringtonine, and ursolic acid of the Hippo pathway, specifically YAP/TAZ, in several cancer therapies. This will enhance the discovery of novel Hippo inhibitors and the optimal therapeutic application of Hippo signaling-related pharmaceuticals in synergistic cancer therapies.

 anticancer cancer therapy hippo signaling pathway natural compounds YAP/TAZ The author(s) declared that financial support was received for this work and/or its publication. section-at-acceptance Experimental Pharmacology and Drug Discovery Introduction

The hallmark of cancer is the existence of cells that are rapidly and continuously dividing. In the past, conventional therapies such as surgery and chemotherapy were the only methods to treat cancer. However, the identification of tumor suppressor genes and oncogenes has led to the idea that drugs or pharmaceuticals can be used to target individual proteins for cancer therapy (Senga and Grose, 2021). Recent progress in emerging technologies such as next-generation sequencing and multi omics analysis has elucidated the intricate relationship of signaling pathways that create complex networks within cells that, when comprehensively mapped, can be used for enhanced targeted therapeutics (Yip and Papa, 2021). Over the past 20 years, many researchers have come to understand the importance of Hippo signaling. This attempt included searching for the mammalian equivalents of this pathway and how they interact with other important signaling cascades that play a crucial role in cell proliferation and survival. Furthermore, the association of Hippo signaling with the regulation of intracellular and extracellular signals was explored, where potential therapeutic interventions could be targeted (Fu et al., 2022).

The Hippo signaling is a very well-preserved pathway that helps cells grow, die, and change into other types of cells. It gets its name from the protein kinase Hippo (Hpo), which is its key part. It signifies one of the latest identified routes that restrict organ size (Harvey et al., 2013; Guo et al., 2025). One of the more well-known pathways is the Salvador-Warts-Hippo signaling cascade, which contain Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) (Harvey and Tapon, 2007). A multitude of cellular functions, tissue homeostasis, and the growth of organs in the balanced condition are all dependent on the YAP/TAZ complex (Mokhtari et al., 2023; Hillen et al., 2024). Nevertheless, it has been demonstrated that these transcriptional coactivators serve as important tumorigenic drivers that facilitate migration, boost cellular proliferation, inhibit apoptosis, and connect extracellular signals to gene expression programs. Consequently, YAP and TAZ offer a significant opportunity for the development of treatments aimed at this pivotal pathway (Ghaboura, 2025; Talukdar et al., 2025).

Attempts have been made to develop novel agents from plants to prevent cancer metastasis and invasion (Zhang et al., 2024; Wang et al., 2023). Nevertheless, due to concomitant toxicity, adverse side effects, and diminished selectivity and specificity, few have received approval. Consequently, there is an increasing need to investigate innovative anticancer agents to combat cancer (Abdellatef et al., 2022). The recent identification of naturally occurring phytochemicals with significant anticancer properties found in food-based diets has led to the development of chemotherapy regimens that use these compounds alongside conventional chemotherapy drugs. It has been suggested that approximately one-third of malignancies may be averted by dietary regulations and consistent physical exercise (Farahmand et al., 2017).

Moreover, numerous obstacles related to the efficient and secure application of these natural phytochemicals have been surmounted by innovative methodologies employed in the pharmaceutical sector (Atanasov et al., 2021). Natural substances that have been shown to fight cancer in the past are now great candidates for anticancer medications since they are less toxic and work well against many types of cancer (Dehelean et al., 2021; Hołota and Posmyk, 2025).

Among these widely recognized phytochemicals are apigenin, curcumin, resveratrol, green tea polyphenols, soy isoflavones, and artemisinin; they are all members of the class of bioactive substances known as “phytochemicals” (Rai et al., 2025). Thus, diets containing various phytochemicals have been suggested to yield more pronounced effects, and may serve as a primary defense against cancer. Conversely, certain phytochemicals, such as curcumin, can confer DNA protection against damage during radiotherapy and offer a prolonged protective effect. Studies have indicated that phytochemicals, when used independently and not in conjunction with chemotherapies, can exhibit anticancer properties (Sohel et al., 2023). These distinctive effects are partially attributed to their inhibitory impact on the Hippo signaling, which regulates epithelial-mesenchymal transition (EMT), the proliferation of cancer stem cells (CSCs) and metastasis (Huang et al., 2020; Ordaz-Ramos et al., 2023).

Moreover, a growing body of research has examined the anticancer activity of many natural plant-derived substances in relation to their potential functional interactions with Hippo components (You et al., 2022; Bala et al., 2025). A significant number of these studies have indicated that phytochemicals influence the activities of Hippo components, including YAP and TAZ, and their associated anticancer effects, suggesting substantial promise for these drugs in future targeted cancer therapies. Given the scarcity of thorough reviews on this subject, the current study aimed to elucidate the Hippo-related effects of anticancer plant-derived molecules and their prospective applications in cancer therapy (Moloudizargari et al., 2022). The objective of this review is to elucidate the Hippo pathways implicated in cancer development, followed by an examination of the diverse effects of phytochemicals with significant modulatory properties on this particular pathway associated with cancer development, stemness, and metastasis.

 An overview of hippo signaling pathway

Similar to other intercellular signaling pathways, the majority of the components and fundamental signal transduction mechanisms linked to Hippo signaling were initially found in fruit fly, or Drosophila, and subsequently demonstrated to be conserved in other animal species. This pathway has been the subject of increasing research over the last 15 years because of its important regulatory effects on growth, regeneration, and cancer-promoting functions (Misra and Irvine, 2018).

The Hippo pathway in mammals include YAP, mammalian Ste20-like kinase 1/2 (MST1/2), sav family WW-domain containing protein 1 (SAV1), large tumor suppressor 1/2 (LATS1/2), and/or its counterpart TAZ, which is encoded by the WW domain-containing transcription regulator 1 (WWTR1) gene. The striatin (STRN)-interacting phosphatase and kinase (STRIPAK) complex typically functions upstream of kinase kinase kinases (MAP4Ks) and MST1/2, thereby inhibiting the Hippo signaling pathway (Bae et al., 2017; Chen et al., 2019). In contrast, activation of the Hippo signaling involves MST1/2, MAP4Ks, and its scaffold protein SAV1, which phosphorylate LATS1/2 and its scaffold MOB1A/B (Zheng et al., 2015). Following activation, LATS1/2 phosphorylates and inhibits YAP and TAZ, thereby obstructing their movement into the nucleus for interaction with TEAD 1–4 (Badouel and McNeill, 2011). MST1 and MST2 are serine/threonine kinase whose activity is augmented when they bind to the scaffold protein SAV1 via their C-terminal domains (Sav/Rassf/Hpo) (Yu and Guan, 2013). MST1/2 also promotes the interaction between MOB1A/B and LATS1/2. Recent findings indicate that WWC proteins facilitates this process by acting as scaffold proteins (Qi et al., 2022). Moreover, apart from MST1/2, several proteins in the MAP4K family have been implicated in the stimulation of LATS1/2 (Meng et al., 2015; Yang et al., 2024). Thus, MST1/2 or MAP4K proteins stimulation initiates the Hippo signaling. The simultaneous depletion of these protein significantly obstructs downstream signaling (Plouffe et al., 2016). MOB1A/B performed two distinct roles in activation of Hippo signaling. The first role is to facilitate the interaction of MST1/2 and LTS1/2 by serving as a scaffold. Furthermore, modified MOB1A/B promotes the stimulation of LATS1/2 by causing a conformational alteration in LATS (Ando et al., 2021; Praskova et al., 2008). LATS1/2 are serine/threonine kinases belonging to the AGC kinase family. They engage in direct interaction with YAP/TAZ after stimulation. WW domains on LATS1/2 have been proposed as potential mediators of this interaction (Furth and Aylon, 2017; Moroishi et al., 2016). Strong evidence indicated that activated LATS1/2 phosphorylate and deactivate YAP and TAZ, the primary downstream regulators of the Hippo signaling (Basak and Ain, 2022).

In response to stimulation of the Hippo pathway, YAP/TAZ activity is downregulated which further resulted in YAP/TAZ degradation in the cytoplasm. In contrast, when Hippo signaling is inhibited, unphosphorylated YAP/TAZ migrates to and aggregates in the nucleus, where they engage with TEA domain (TEAD) transcription factors to modulate target gene expression and promote cell proliferation and survival (Kim et al., 2023; van Soldt and Cardoso, 2020) (Figure 1).

An overview of the Hippo signaling pathway in activated and non-activated state.

Diagram comparing Hippo signaling pathways. On the left, the "Hippo Signaling On Stage" shows active MST1, SAV1, LATS1/2, MOB1, and YAP/TAZ leading to degradation and target genes off. On the right, the "Hippo Signaling Off Stage" shows inactive MST1, SAV1, LATS1/2, and MOB1, allowing YAP/TAZ to enter the nucleus, activating target genes.

Numerous context-dependent functions of YAP have been documented and examined (Cunningham and Hansen, 2022). It has been demonstrated that YAP/TAZ interacts with several transcription factors, including p73, RUNT-related transcription factors (RUNX1 and RUNX2), SMAD1, SMAD2/3, SMAD7, and T-box transcription factor 5 (TBX5) (Boopathy and Hong, 2019). Additional studies of Hippo and TGF-β interactions suggest that TAZ/YAP can influence TGF-β receptor activation and enhance nuclear retentivity (Labibi et al., 2020). In response to stress, the critical energy indicator component AMP-activated protein kinase (AMPK) promptly phosphorylates and suppresses YAP and TAZ by inhibiting their association with TEAD (Koo and Guan, 2018). Notch signaling pathway is also regulated by YAP/TAZ mediated upregulation expression of Jagged1 (Kim et al., 2017). YAP/TAZ also identified as a constituent of a deleterious complex within the Wnt/β-catenin pathway. The nuclear translocation of YAP/TAZ resulted in β-catenin mediated upregulation of various target genes, which collaboratively promotes cell growth and tumor progression (Yang D. et al., 2021; Rosenbluh et al., 2012).

It is widely recognized that TEADs are important element of YAP/TAZ action. TEAD possesses a “TEA” DNA binding site that interacts with the target genes stimulators, as well as a YAP/TAZ binding site that connects with transcription associated cofactors. The phosphorylation at cysteine residues of N- and C- terminal site has been demonstrated to impact the stability of TEADs and expression of target genes (Noland et al., 2016; Chan et al., 2016). Stress induced p38/mitogen activated protein kinase (MAPK) has been shown to have significant impact on the nucleocytoplasmic shuttling of TEADs (Lin et al., 2017). Vestigial-like family member 4 (VGLL4) inhibits YAP activity by obstructing its TEAD binding site. T-cell lymphoma invasion and metastasis 1 (TIAM1) interrupts the YAP/TAZ-TEAD interaction by interacting with YAP/TAZ (Yamaguchi and Taouk, 2020). In response to Hippo pathway downregulation, YAP/TAZ migrates to nucleus and binds to TEADs, activating target genes such as cysteine rich protein 61 (CYR61), AXL, and CTGF. Activation of these gene resulted in augmented cell proliferation and development (Allegra et al., 2021; Choi and Kim, 2024).

 Hippo signaling pathway and tumorigenesis: from the lens of YAP/TAZ and TEAD

The Hippo signaling pathway is frequently dysregulated in various cancer types; however, mutations in this pathway are comparatively uncommon. Inactivation of components of the core kinase module occurs through mutations in prevalent cancer types, but these events are rare and typically found in less than 10% of cancer cases (Wang et al., 2018; Li and Guan, 2022). The direct role of the pathway in initiating and advancing cancer is evident in animal models, where YAP/TAZ hyperactivity induces various cancer types and metastasis, as well as in certain rare human cancers characterized by frequent loss-of-function mutations and deletions of kinase module genes (Table 1).

Association of various targets of Hippo signaling pathway including YAP, TAZ, MST and LATS in multiple carcinomas.

Cancer Cancer model Key component (s) Modulatory effect References
Breast cancer In vitro, in vivo TAZ, MST and LATS Stimulated self-renewal and tumor-initiation capacities Cordenonsi et al. (2011)
In vitro, clinical samples TAZ Association with EMT and metastasis Díaz-Martín et al. (2015)
In vitro, in vivo YAP/TAZ Stimulated self-renewal and tumor-initiation capacities Kim T. et al. (2015)
Cholangiocarcinoma In vitro, in vivo YAP Induced EMT and cancer progression Pei et al. (2015)
Cervical cancer In vitro YAP and TAZ Induced proliferation, migration and invasion Patterson et al. (2024)
Cervical cancer and colon cancer In vitro TAZ/YAP Induced proliferation, migration and invasion Arioka et al. (2025)
Glioblastoma In vitro, in vivo YAP/TAZ Stimulated plasticity and stemness Castellan et al. (2021)
In vivo, clinical samples YAP/TAZ Enhanced tumorigenesis and malignant form of glioblastoma Yang et al. (2023)
Hepatocellular carcinoma In vitro, in vivo, clinical samples YAP Induced MDR through RAC1-ROS-mTOR pathway and repression of autophagy-mediated cell death Zhou et al. (2019)
In vivo YAP/TAZ Enhanced tumor growth Moya et al. (2019)
In vitro, clinical samples YAP/TAZ Tumor cell migration and invasion Weiler et al. (2020)
Lung cancer In vitro, clinical samples YAP Induced EMT, metastasis and cancer progression Guo et al. (2017)
Clinical samples YAP Enhanced tumor progression Kim et al. (2011)
Osteosarcoma In vitro, clinical samples YAPl Stimulated the proliferation and invasion through RUNX2 pathway Zhang et al. (2013)
Clinical samples YAP/TAZ Enhanced tumor progression Bouvier et al. (2016)
Prostate cancer In vitro, in vivo YAP1 Enhanced tumor progression Kuser-Abali et al. (2015)
In vitro, clinical samples YAP1 Modulatory effects on PSA expression through the AR Wang et al. (2024)
In vitro, in vivo YAP Augmented castration resistant growth as well as invasion and migration Zhang et al. (2015)

The onset and progression of cancer are complex processes involving numerous elements. Abnormal modification in the hippo pathway are frequently observed in various cancer types in both human and animal models, including breast, colorectal, lung, brain, uveal and esophageal cancers, particularly related to dysregulation of YAP/TAZ/TEAD axis (Han et al., 2019a; Plouffe et al., 2015). For instance, the formation of glioma was linked to the of YAP/TAZ abnormal activation, which was caused by the downregulation of LATS1/2 (Zhang et al., 2016). A novel crosstalk mechanism between the Hippo/YAP and Wnt/β-catenin pathways has recently been identified, which plays a functional role in glioma proliferation (Wang et al., 2017). In hepatocellular carcinoma patients, upregulated activity of YAP/TAZ have been associated with aggressive molecular characteristics and poor outcome negative survival outcomes (Perra et al., 2014). Unlike YAP, there is a scarcity of studies examining the role of TAZ in various malignancies. However, Yang L. et al. (2021) indicated that nuclear transfer of TAZ is linked to an extremely aggressive triple-negative variant of breast carcinoma. Moreover, hyperactivation of TEAD and associated proteins were shown to exert a significant influence on carcinogenesis process. TEAD1 is known to be an important controlling element in the differentiation of prostatic epithelial cells and morphogenesis of epithelial cells. Higher levels of TEAD1 have been linked to worse prognosis in patients with prostate cancer (Shen et al., 2020; Song et al., 2024), while higher levels of TEAD2 can cause hepatocellular carcinoma (Joo et al., 2020). In addition to prevalent malignancies, other concurrent upregulation of YAP/TAZ has been documented to play crucial roles in the development of some uncommon cancers in a context-dependent manner. The TAZ-CAMTA1 fusion protein was detected in over 90% of patients with epithelioid hemangioendothelioma (EHE) because of highly prevalent gene mutation (translocation) (Suto, 2024). There are several ways in which upregulated activity of YAP/TAZ/TEAD complex promotes carcinogenesis. In many cancer cell lines, AP-1-linked gene expression process are important for cell cycle regulation, and the YAP/TAZ-TEAD complex is required for these programs to function properly. In addition, the complex can aberrantly control cell cycle related transcription factors like AP-1, leading to overproliferation, cellular migration, and metastasis (Zanconato et al., 2015). Also, hyperactive YAP/TAZ controls the transcription of metabolic genes that can increase the transport of glucose and amino acids that resulted in a metabolic change towards aerobic glycolysis and helps in tumor growth in situations with limited nutrients (Cox et al., 2018). Moreover, these abnormal metabolic pathways may subsequently facilitate YAP/TAZ activation, thereby promoting the onset and progression of many malignancies (Zhang et al., 2018).

Furthermore, YAP/TAZ is an important element of EMT, a mechanism that stimulates cells to detach from their surface and adapt an invasive and motile phenotype (Zhang et al., 2021). Epithelial-mesenchymal transition (EMT) facilitates the dissemination of cancer cells to distant sites, hence enhancing metastasis (Fedele et al., 2022). YAP/TAZ modulates EMT by modifying the expression of crucial proteins, including ZEB1/2, Twist, and Snail (Ichikawa et al., 2022). These interactions upregulated the level of mesenchymal markers (vimentin and N-cadherin) and downregulated the level of epithelial markers (E-cadherin) (Bullock and Brunton, 2025). Examination of cancer-specific YAP/TAZ signaling impacts on tumor aggressiveness and epithelial-mesenchymal transition. YAP/TAZ increases resistance to anticancer agents and augmented migratory potential in lung cancer (Franklin et al., 2023). The augmentation of stemness and plasticity in breast carcinomas by YAP/TAZ facilitates immune evasion and adaptation to adverse environments (Guo and Han, 2023). YAP/TAZ facilitates mechanotransduction in liver cancer, allowing cancer cells to adapt to heightened tissue stiffness, a significant characteristic of hepatocellular carcinoma (Xuan et al., 2025). Similar to ovarian and renal malignancies, dysregulation of YAP/TAZ serves as a prognostic indicator of poor outcomes, suggesting its role in metastatic advancement and resistance to pharmacological therapies (Piccolo et al., 2023).

However, several reports have suggested that they are not functionally redundant in cancer. Deletion of YAP or TAZ causes different phenotypes that cannot be rescued by the other, indicating specialized functions of each regulator (Plouffe et al., 2018). Further genome-wide studies have revealed that YAP and TAZ regulate overlapping but distinct sets of gene, pointing to differences in how they select enhancers and recruit other regulatory cofactor (Reggiani et al., 2021). In cancer, YAP primarily drives tumor growth and proliferation. In contrast, TAZ is more strongly linked to increased cell invasion, epithelial-mesenchymal transition, and cancer stem cell traits, particularly in advanced tumors (Shreberk-Shaked and Oren, 2019). These findings collectively show that YAP and TAZ are distinct carcinogenic regulators whose roles depend on biological context.

Recent research has elucidated new aspects of the Hippo pathway, particularly the role of YAP/TAZ/TEAD in carcinogenesis, thereby creating new opportunities for therapeutic interventions. The information gathered from these investigations offers fresh perspectives on the intricacy of cancer and may result in development of more treatment methods that specifically target the Hippo pathway (Yu et al., 2025).

 Anticancer natural compounds as modulators of hippo signaling

The Hippo signaling is crucial in regulating organ size and tumorigenesis by suppressing cell proliferation, promoting apoptosis, and modulating the development of stem cells (Barry et al., 2021). The accumulation of unphosphorylated YAP/TAZ in the nucleus results in tumor growth and development. The cytoplasm serves as the primary site for phosphorylated YAP/TAZ, inhibiting cancer proliferation. There is a correlation between various malignant tumors and enhanced activity and expression of YAP/TAZ (Mohajan et al., 2021). The advancement of targeted Hippo pathway interventions for cancer chemoprevention and treatment using natural chemicals remains in its nascent phases, although it holds significant promise for the future (Mohammadi et al., 2020; Charoenwongpaiboona et al., 2021). Apart from other studies, we therefore examined recent advancements in the application of extremely effective anticancer phytochemicals (apigenin, curcumin, EGCG, resveratrol, homoharringtonine, and ursolic acid) to target Hippo components in cancer treatment (Table 2) (Figure 2).

Effects of various plant derived anticancer compounds on cellular and molecular targets of Hippo signaling pathway in different types of carcinomas.

Anticancer compound Class Cancer type Cancer model Target References
Apigenin [C15H10O5 Chemical structure of quercetin, featuring three benzene rings connected. Each ring has various hydroxyl (OH) groups attached. An oxygen double bond is present on one ring, indicating a ketone group. Polyphenols Hepatocellular carcinoma SMMC-7721 and SK-Hep1 cells Downregulated expression of YAP Zeng et al. (2022)
Polyphenols Breast cancer MDA-MB-231 cells Downregulated activity of YAP/TAZ and transcriptional activation of CTGF and CYR61 genes Li Y. W. et al. (2018)
Curcumin [C21H20O6] Chemical structure of curcumin, featuring two phenolic rings connected by a linear chain with conjugated double bonds and two keto groups. Each phenolic ring has a methoxy group and a hydroxyl group attached. Polyphenols Pancreatic cancer Patu8988 and Panc-1 cells Downregulated expression of YAP/TAZ Zhou et al. (2016)
Polyphenols Colon cancer HCT116 and SW620 cells Downregulated expression of YAP Zhu et al. (2018)
Polyphenols Bladder cancer 5637 and WH cells Downregulated YAP/TAZ level Gao et al. (2014)
Polyphenols Lung cancer A549, NCI-H1299 cells Induced TAZ protein degradation Zheng et al. (2021)
Epigallocatechin-3-gallate [C22H18O11] Chemical structure of curcumin, showing three aromatic rings connected by two alpha, beta-unsaturated carbonyl groups. Hydroxyl groups attached to rings and an ethylene bridge with a double-bonded oxygen. Polyphenols Tongue squamous cell carcinoma CAL27 and SCC15 Downregulated expression of TAZ, LATS1 and MOB1 Li A. et al. (2018)
Resveratrol [C14H12O3] Chemical structure of resveratrol, featuring two interconnected benzene rings with three hydroxyl (HO) groups attached: one at the top of the first ring and two on opposite ends of the second ring. The rings are connected by a double bond with two hydrogen atoms. Polyphenols Colon cancer HCT116 cells Downregulated expression of I YAP and its downstream targets CTGF and CYR61 Qin et al. (2022)
Polyphenols Gastric cancer SGC-7901 cells Downregulated expression of YAP Deng et al. (2022)
Polyphenols Thyroid cancer Nthy-ori 3-1 and FTC133 cells; FTC238 cells xenograft Downregulated expression of YAP/TAZ Xu et al. (2020)
Homoharringtonine [C29H39O9] Chemical structure diagram of a complex organic molecule featuring multiple fused rings and several oxygen atoms. The structure includes hexagonal and pentagonal shapes, along with single, double, and wedge bonds indicating three-dimensional positioning. Alkaloid Hepatocellular carcinoma HepG2, Huh7, SMMC-7721 cells Upregulated phosphorylation of MST1, MST2, MOB1, LAST1, and YAP Wang et al. (2021)
Ursolic acid [C30H48O3] Chemical structure of ursolic acid, featuring a series of connected hexagonal and pentagonal rings. Notable functional groups include hydroxyl groups (OH) in red, and a carbonyl group (C=O) on the left. Terpenoid Gastric cancer SNU484 and SNU638 cells Upregulated protein expression of RASSF1, MST1, MST2, LATS1, and while YAP1, CTGF FOXM1, KRAS, and BATF expression decreased Kim et al. (2019)

Modulatory effects of plant derived anticancer compounds (apigenin, curcumin, EGCG, resveratrol, homoharringtonine, and ursolic acid) on MST1/2, LATS1/2, MOB1, YAP and TAZ proteins of signaling pathway.

Diagram illustrating the inhibition of the YAP/TAZ signaling pathway in the cytoplasm and nucleus, showing interactions with compounds like homoharringtonine, ursolic acid, EGCG, apigenin, curcumin, and resveratrol, leading to the inactivation of target genes. Apigenin

Apigenin is a naturally occurring flavonoid that is classified under the flavone category of glycosides. It is commonly found in various vegetables, fruits, and herbs such as oranges, grapefruit, onions, parsley, chamomile and basil (Salehi et al., 2019). A number of studies have shown that apigenin may have antioxidant and anti-inflammatory effects which makes it an attractive candidate for lowering the risk of pathogenesis (Lee et al., 2023; Charrière et al., 2024; Lu et al., 2023). Additionally, apigenin has been demonstrated to boost the internal defense against oxidative stress by increasing the function of key enzymes (Gao et al., 2012). Based on the results of multiple studies, this phytochemical has the potential to suppress angiogenesis, invasion and migration, induce apoptosis and cell cycle arrest which ultimately suppress a variety of cancers (Zhang et al., 2024; Bhagavatula et al., 2024; Pandey et al., 2023; Golonko et al., 2024). Furthermore, apigenin exhibit antitumor effects through upregulation of caspases, Bax, p53, and TNF-α and the downregulation of Bcl-2, cyclins, CDKs and MMP-2/-9 (Liang et al., 2022). It is also involved in the modulation of key intermediates of signaling pathways, such as the reduction of PI3K/AKT, mTOR, NF-κB, JNK, STATs, β-catenin, and Notch1 levels (Maashi et al., 2022; Chen et al., 2022).

Apigenin therapy suppressed the viability, migration, and invasion of HCC SMMC-7721 and SK-Hep1 cells in vitro. It diminished YAP expression, thereby decreasing migration and invasion by altering EMT indicators, and enhanced autophagy in liver cancer cells by regulating autophagy-related gene expression (Zeng et al., 2022). Mechanistic investigation revealed that apigenin markedly inhibited the proliferation and migration of TNBC cells. In breast cancer cells, apigenin treatment downregulated the activity of YAP/TAZ as well as the expression of CYR61 and CTGF target genes. Moreover, apigenin inhibited the interaction of YAP/TAZ/TEAD proteins and reduced TAZ expression, thereby sensitizing breast cancer cells to apigenin therapy (Li Y. W. et al., 2018).

 Curcumin

Curcumin has demonstrated anti-inflammatory, antioxidant, antibacterial, antitumor, and antimutagenic activities, making it as suitable supplement for various ailments. Numerous reports from the past few decades have suggested that curcumin has strong potential against multiple types of cancer (Amaroli et al., 2024). It regulates a variety of growth regulators, transcription factors, inflammatory factors (cytokines), and cell signaling molecules, and hence inhibits the growth and spread of different forms of cancers (Kunnumakkara et al., 2008). Curcumin has attracted considerable interest because of its possible anticancer effects, both independently and in conjunction with chemotherapeutic drugs. Recent research has emphasized its capacity to impede multiple phases of carcinogenesis, including angiogenesis, tumor promotion, tumor growth (Parker et al., 2025).

A molecular-based investigation showed that curcumin therapy markedly decreased cell proliferation, diminished clonogenic potential, obstructed migration and invasion, and triggered cell cycle arrest and apoptosis in pancreatic cancer cells. In addition to this, curcumin significantly reduced the expression of YAP and TAZ, which in turn lowered the expression of Notch-1 (Zhou et al., 2016). Zhu et al. investigated whether YAP serves as a target of curcumin in colon cancer cells. The results demonstrated that curcumin suppressed cell growth and triggered autophagy in colon cancer cells. It was observed that the expression of YAP was decreased following treatment with curcumin. Furthermore, autophagy was suppressed upon overexpression of YAP, whereas a reduction in YAP expression triggered autophagy. This study suggests that curcumin could be a good treatment for colon cancer since it might be able to stop YAP and reverse autophagy (Zhu et al., 2018).

A therapeutic investigation of curcumin demonstrated that it facilitates the proteasome-dependent degradation of KLF5 by targeting the YAP/TAZ pathway in bladder cancer cells. This study revealed that lentivirus-mediated knockdown of KLF5 suppressed cancer cell proliferation, whereas overexpression of Flag-tagged KLF5 partially counteracted the curcumin effects on cell proliferation and cyclin D1 level. Moreover, curcumin may inhibit the production of Hippo pathway effectors, YAP and TAZ, which are known to safeguard KLF5 from destruction (Gao et al., 2014). Zheng et al. conducted additional research to understand the mechanistic role of curcumin against lung cancer cells by focusing on elements of the hippo pathway that are significantly important. Mechanistically, curcumin has been shown to facilitate the nuclear-cytoplasmic translocation of TAZ, but not YAP, which are the crucial elements of the Hippo pathway. Furthermore, curcumin impaired TAZ protein stability and facilitated TAZ protein breakdown in lung cancer cells, relying on the proteasome degradation system rather than the autophagic-lysosomal degradation route. When TAZ was overexpressed, it restored the ability of curcumin to suppress the stemness of lung cancer cells (Zheng et al., 2021).

 Epigallocatechin gallate

Among the several flavonoids present in green tea is epigallocatechin gallate, more commonly known as EGCG. Extensive research has been conducted on EGCG to investigate its possible health benefits, particularly in the context of cancer. Preclinical experimental evidences suggests that EGCG may have growth inhibitory, anti-angiogenic, and apoptotic inducing effects in various cancer models (Almatroodi et al., 2020). EGCG can disrupt many signaling pathways linked to cellular proliferation and division across distinct cancer types. An increasing amount of evidence indicates that EGCG may address many cancer hallmarks, which are the essential biological processes and characteristics that facilitate cancer formation and progression (Farooqi et al., 2020; Talib et al., 2024). A plethora of in vitro investigations have demonstrated the efficacy of EGCG in attenuating proliferation, inducing apoptosis, and obstructing the migration and invasion of tongue squamous cell carcinoma cell lines via several molecular signaling pathways (Ch et al., 2012; Kanlaya et al., 2016; Shin et al., 2016). Li et al. investigated the potential links between EGCG stimulation and TSCC cell Hippo-TAZ signaling pathway activation in this regard. EGCG suppressed the proliferation of TSCC CAL27 and SCC15 cells by reducing the expression of LATS1, MOB1, TAZ and JNK at protein levels. Upregulation of TAZ reduced the effect of EGCG molecule in TSCC CAL27 cells. Furthermore, the combinatorial effect of EGCG and simvastatin significantly decreased cell growth, invasion and migration, while promoting apoptosis in CAL27 cells as compared to individual EGCG treatment (Li A. et al., 2018).

 Resveratrol

Resveratrol, a natural bioactive compound found in grapes, red wine, and many other plant sources, has garnered considerable attention for its antineoplastic capabilities (Meng et al., 2020). The diverse range of cellular and molecular pathways involved in these features render resveratrol a promising anticancer agent against various malignancies such as breast, cervical, prostate, lung, and gastrointestinal cancers. In order to exert its anti-carcinogenic effects, resveratrol interacts with a wide variety of cellular signaling pathways that are associated with a wide variety of tumorigenesis processes, including cell proliferation, apoptosis, angiogenesis, cell cycle regulation, and metastasis (Almatroodi et al., 2022). Resveratrol also shown to inhibits oncogenic genes, stimulated tumor suppressing genes and modify tumor microenvironment (Peng and Jiang, 2018; Han et al., 2019b). Resveratrol also suppresses key oncogenic signaling pathways such as PI3K/AKT/mTOR, NF-κB, and STAT3 (Varoni et al., 2016).

A study by Qin et al. (2022) found that resveratrol treatment significantly decreases cell proliferation and causes cell cycle arrest and apoptotic induction in HCT116 cells. Further mechanistic exploration studies revealed that resveratrol downregulated the YAP protein level and downstream targets CTGF and CYR61 gene expression. Molecular docking analysis suggested a strong interaction of resveratrol with YAP-TEAD. Deng et al. (2022) also explored the antitumor efficacy of resveratrol by targeting Hippo-YAP signaling pathways in gastric cancer SGC-7901 cells. The results shown that resveratrol inhibited cell proliferation, migration and EMT of SGC-7901 cells. A downregulated expression of YAP was also reported in resveratrol treated- SGC-7901 cells, which resulted in deactivation of the Hippo-YAP pathway (Deng et al., 2022). Moreover, Xu et al. demonstrated that resveratrol may impede follicular thyroid cancer via a mechanism associated with direct interaction with ST6GAL2 and the Hippo pathway. The findings suggested that ST6GAL2 expression was downregulated in follicular thyroid carcinoma following resveratrol treatment as compared to control cells, implying resveratrol plays a role in this mechanism (Xu et al., 2020).

 Homoharringtonine

Homoharringtonine (HHT) is a plant-derived alkaloid which is known for its antitumor efficacy. Recent research has also shown that HHT may have neuroprotective capabilities, in addition to its immunomodulatory, antiviral and antifibrotic effects. HHT has exhibited remarkable potential in clinical studies for the treatment of hematological cancers specifically acute and chronic myeloid leukemia (Khatua et al., 2024; Swerdlow et al., 2016). Additionally, antitumor efficacy of HHT against CML has been established by multiple studies performed in the United States (Quintás-Cardama et al., 2009). A variety of diseases and conditions have shown HHT to be an effective anticancer agent; these include acute promyelocytic leukemia, polycythemia vera, acute promyelocytic leukemia, and central nervous system leukemia (Kantarjian et al., 2013). Its proven antiproliferative effects on various tumor cells including breast, skin, and gastrointestinal cancers (Tang et al., 2021; Guo et al., 2021).

In hepatocellular carcinoma cells, HHT markedly suppressed tumor cell growth, migration and invasion, as well as colony forming ability by activating the Hippo pathway. HHT exposure resulted in elevated rate of phosphorylation of major key proteins of the Hippo pathway including YAP, MST1/2, and MOB1. Moreover, HHT treatment leads to increased expression of SAV1. Overall, this study suggested that the Hippo pathway mediates the growth inhibitory role of HHT in hepatocellular carcinoma (Wang et al., 2021).

 Ursolic acid

Ursolic acid is a pentacyclic triterpene that is extracted from numerous vegetables, fruits, and various traditional medicinal herbs (Arulnangai et al., 2025). Ursolic acid has been widely utilized in cancer therapy in Traditional Chinese Medicine (TCM) for numerous years. Over the past two decades, ursolic acid has been evaluated for its efficacy in preventing cancer progression and as a therapeutic intervention for several malignant tumors. Most studies have focused on its effects on energy metabolism, cellular proliferation, and antioxidant activities (Nguyen et al., 2021; Prasad et al., 2016; Kim S. H. et al., 2015; Chen et al., 2020). These preclinical investigations have demonstrated that ursolic acid decreases various aspects of cancer cell proliferation, energy metabolism, and inflammation generated by tumor cells (Wang et al., 2013; Kim et al., 2014; Zhao et al., 2021; Zafar et al., 2022).

Kim et al. revealed the mode of action of ursolic acid in gastric cancer cells by modulating the Hippo pathway. Their findings shows that the colony counts and dimensions of cancer cells were significantly reduced following the administration of ursolic acid. Ursolic acid also repressed the invasion and migratory rates of these cells. The findings of gene ontology analysis indicated that several key intermediates of Hippo pathway were effectively altered by ursolic acid including MST1, MST2, YAP1, and LATS1. Furthermore, the protein expression analysis were in accordance with the findings of gene ontology analysis. In xenograft tumor model, ursolic acid treatment resulted in elevated levels of Hippo pathway-associated proteins, thus demonstrating its potential to inhibit gastric tumors in vivo (Kim et al., 2019).

 Limitations

The use of plant derived compounds has demonstrated significant promise in cancer therapy due to their diverse mechanisms, which include antioxidant, antiproliferative and immunomodulatory effects (Ai et al., 2024). Many phytochemicals possess notable anticancer properties, however they often lack drug like characteristics, obstructing their clinical application. A major limitation is their poor aqueous solubility with over 40% of plant derived compounds exhibiting insufficient aqueous solubility, which restricts their absorption in gastrointestinal tract and reduces systemic circulation (Nicolaescu et al., 2025). Additionally, once absorbed, many phytochemicals undergo swift first pass metabolism in the liver and intestines, leading to quick degradation and elimination from the body (Devaraji and Thanikachalam, 2025). The unstable nature of these natural compounds such as curcumin and quercetin, further decreases their bioavailability before they reach their target sites (Aljabali et al., 2025). Limited membrane permeability and non-specific distribution hinder their accumulation at tumor sites, hence increasing the risk of adverse effects in nearby areas. The medicinal potential of these phytochemicals is constrained by challenges related to solubility, stability and bioavailability. To address these challenges and fully harness the therapeutic benefits of phytochemicals, it is essential to develop better delivery carriers that can protect them, enhance their absorption and enable targeted actions (Peñaherrera-Pazmiño et al., 2025).

 Conclusion and future trends

Recently, numerous insights into the Hippo pathway have explored its mechanism of activation, crucial regulators, and upstream and downstream targets, thereby enhancing our understanding of the involvement of this pathway in several types of carcinomas. Thus, targeting this pathway and its regulators could be a promising strategy for anticancer therapy. This review highlights the recent research reports on key anticancer phytochemicals, including apigenin, curcumin, EGCG, resveratrol, homoharringtonine, and ursolic acid that modulate the Hippo-YAP/TAZ signaling pathway. In most cancer types, altered expression of YAP and TAZ is associated with drug resistance, tumor growth, metastasis, and EMT. Considering the potential role of Hippo-YAP/TAZ signaling, efforts are being made to discover various agents that target this pathway. In this context, the application of phytochemicals has demonstrated significant potential in inhibiting cancer cell growth by targeting YAP/TAZ and other regulators of the Hippo pathway. However, research focusing on this pathway is in its early stages, and the majority of the natural compounds examined in this review have been investigated in preclinical studies. While preclinical experimental studies have provided insights into the influence of phytochemicals on Hippo-YAP/TAZ signaling pathway, there is still a need for a more profound understanding of how these compounds modulate these factors, consequently enhancing their therapeutic efficacy. The main goal of future research should be to transform preclinical results into clinical outcomes. Further exploration of the mechanisms behind natural compounds-based targeting of Hippo pathway could yield valuable insights and potentially open the new avenue to innovative combinatorial therapies, improved drug delivery methods that explore the unique properties of these compounds.

 Author contributions

DE: Conceptualization, Formal Analysis, Methodology, Visualization, Writing – original draft, Writing – review and editing. PP: Conceptualization, Formal Analysis, Supervision, Validation, Writing – original draft, Writing – review and editing. KA: Formal Analysis, Methodology, Project administration, Visualization, Writing – review and editing. AA: Conceptualization, Supervision, Validation, Visualization, Writing – review and editing. MS: Formal Analysis, Supervision, Validation, Writing – review and editing. AS: Investigation, Methodology, Validation, Writing – review and editing. FK: Conceptualization, Supervision, Validation, Writing – original draft, Writing – review and editing.

 Acknowledgements

The authors express their gratitude to the Deanship of Scientific Research at King Khalid University for funding this work through the Large Research Group Project under grant number RGP.02/725/46.

 Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited by: Rabea Parveen, Jamia Hamdard University, India

Reviewed by: Zhao Huang, Sichuan University, China

Dr.Mukul Machhindra Barwant, Commerce and Science College, India

 References Abdellatef A. A. Meselhy M. R. El-Askary H. I. El-mekkawy S. Hayakawa Y. (2022). Anti-metastatic function of triterpene phytochemicals from guggul by targeting tumor-intrinsic NF-kB activation in triple-negative breast cancer cells. Phytomedicine Plus 2 (4), 100345. 10.1016/j.phyplu.2022.100345 Ai Z. Liu B. Chen J. Zeng X. Wang K. Tao C. (2024). Advances in nano drug delivery systems for enhanced efficacy of emodin in cancer therapy. Int. J. Pharm. 9, 100314. 10.1016/j.ijpx.2024.100314 39834843 Aljabali A. A. A. Obeid M. A. Bashatwah R. M. Qnais E. Gammoh O. Alqudah A. (2025). Phytochemicals in cancer therapy: a structured review of mechanisms, challenges, and progress in personalized treatment. Chem. Biodivers. 22 (8), e202402479. 10.1002/cbdv.202402479 40192260 Allegra A. Pioggia G. Innao V. Musolino C. Gangemi S. (2021). New insights into YES-associated protein signaling pathways in hematological malignancies: diagnostic and therapeutic challenges. Cancers (Basel) 13 (8), 1981. 10.3390/cancers13081981 33924049 Almatroodi S. A. Almatroudi A. Khan A. A. Alhumaydhi F. A. Alsahli M. A. Rahmani A. H. (2020). Potential therapeutic targets of epigallocatechin gallate (EGCG), the Most abundant catechin in green tea, and its role in the therapy of various types of cancer. Molecules 25 (14), 3146. 10.3390/molecules25143146 32660101 Almatroodi S. A. A Alsahli M. S M. Aljohani A. Alhumaydhi F. A. Babiker A. Y. (2022). Potential therapeutic targets of resveratrol, a plant polyphenol, and its role in the therapy of various types of cancer. Molecules 27 (9), 2665. 10.3390/molecules27092665 35566016 Amaroli A. Panfoli I. Bozzo M. Ferrando S. Candiani S. Ravera S. (2024). The bright side of curcumin: a narrative review of its therapeutic potential in cancer management. Cancers 16 (14), 2580. 10.3390/cancers16142580 39061221 Ando T. Arang N. Wang Z. Costea D. E. Feng X. Goto Y. (2021). EGFR regulates the hippo pathway by promoting the tyrosine phosphorylation of MOB1. Commun. Biol. 4 (1), 1237. 10.1038/s42003-021-02744-4 34725466 Arioka M. Yi W. Igawa K. Ishikane S. Takahashi-Yanaga F. (2025). Differentiation-inducing factor-1 inhibits EMT by proteasomal degradation of TAZ and YAP in cervical and colon cancer cell lines. Eur. J. Pharmacol. 987, 177184. 10.1016/j.ejphar.2024.177184 39645220 Arulnangai R. Asia Thabassoom H. Vajiha Banu H. Thirugnanasambandham K. Ganesamoorthy R. (2025). Recent developments on ursolic acid and its potential biological applications. Toxicol. Rep. 14, 101900. 10.1016/j.toxrep.2025.101900 39897400 Atanasov A. G. Zotchev S. B. Dirsch V. M. Supuran C. T. (2021). Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 20 (3), 200–216. 10.1038/s41573-020-00114-z 33510482 Badouel C. McNeill H. (2011). SnapShot: the hippo signaling pathway. Cell 145 (3), 484–484.e1. 10.1016/j.cell.2011.04.009 21529719 Bae S. J. Ni L. Osinski A. Tomchick D. R. Brautigam C. A. Luo X. (2017). SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK. Elife 6, e30278. 10.7554/eLife.30278 29063833 Bala R. Madaan R. Bedi O. Singh A. Taneja A. Dwivedi R. (2025). Targeting the Hippo/YAP pathway: a promising approach for cancer therapy and beyond. MedComm 6 (9), e70338. 10.1002/mco2.70338 40895190 Barry E. R. Simov V. Valtingojer I. Venier O. (2021). Recent therapeutic approaches to modulate the Hippo pathway in oncology and regenerative medicine. Cells 10 (10), 2715. 10.3390/cells10102715 34685695 Basak T. Ain R. (2022). Molecular regulation of trophoblast stem cell self-renewal and giant cell differentiation by the Hippo components YAP and LATS1. Stem Cell Res. Ther. 13 (1), 189. 10.1186/s13287-022-02844-w 35526072 Bhagavatula D. Hasan T. N. Vohra H. Khorami S. Hussain A. (2024). Delineating the antiapoptotic property of apigenin as an antitumor agent: a computational and in vitro study on HeLa cells. ACS Omega 9 (23), 24751–24760. 10.1021/acsomega.4c01300 38882173 Boopathy G. T. K. Hong W. (2019). Role of Hippo Pathway-YAP/TAZ signaling in angiogenesis. Front. Cell Dev. Biol. 7, 49. 10.3389/fcell.2019.00049 31024911 Bouvier C. Macagno N. Nguyen Q. Loundou A. Jiguet-Jiglaire C. Gentet J. C. (2016). Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma. Oncotarget 7 (40), 64702–64710. 10.18632/oncotarget.11876 27608849 Bullock E. Brunton V. G. (2025). E-Cadherin-Mediated cell-cell adhesion and invasive lobular breast cancer. Adv. Exp. Med. Biol. 1464, 259–275. 10.1007/978-3-031-70875-6_14 39821030 Castellan M. Guarnieri A. Fujimura A. Zanconato F. Battilana G. Panciera T. (2021). Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma. Nat. Cancer 2 (2), 174–188. 10.1038/s43018-020-00150-z 33644767 Chang C. M. Chang P. Y. Tu M. G. Lu C. C. Kuo S. C. Amagaya S. (2012). Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2. Oncol. Rep. 28 (5), 1799–1807. 10.3892/or.2012.1991 22923287 Chan P. Han X. Zheng B. DeRan M. Yu J. Jarugumilli G. K. (2016). Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat. Chem. Biol. 12 (4), 282–289. 10.1038/nchembio.2036 26900866 Charoenwongpaiboona T. Laowtammathronb C. Lorthongpanichb C. (2021). Therapeutic opportunities for cancers presented by natural and synthetic compounds targeting the Hippo signaling pathway. ScienceAsia 47 (6), 665–672. 10.2306/scienceasia1513-1874.2021.109 Charrière K. Schneider V. Perrignon-Sommet M. Lizard G. Benani A. Jacquin-Piques A. (2024). Exploring the role of apigenin in neuroinflammation: insights and implications. Int. J. Mol. Sci. 25 (9), 5041. 10.3390/ijms25095041 38732259 Chen R. Xie R. Meng Z. Ma S. Guan K. L. (2019). STRIPAK integrates upstream signals to initiate the Hippo kinase cascade. Nat. Cell Biol. 21 (12), 1565–1577. 10.1038/s41556-019-0426-y 31792377 Chen Y. M. Tang B. X. Chen W. Y. Zhao M. S. (2020). Ursolic acid inhibits the invasiveness of A498 cells via NLRP3 inflammasome activation. Oncol. Lett. 20 (5), 170. 10.3892/ol.2020.12027 32934737 Chen Y. H. Wu J. X. Yang S. F. Yang C. K. Chen T. H. Hsiao Y. H. (2022). Anticancer effects and molecular mechanisms of apigenin in cervical cancer cells. Cancers 14 (7), 1824. 10.3390/cancers14071824 35406599 Choi S. H. Kim D. Y. (2024). Regulation of tumor microenvironment through YAP/TAZ under tumor hypoxia. Cancers 16 (17), 3030. 10.3390/cancers16173030 39272887 Cordenonsi M. Zanconato F. Azzolin L. Forcato M. Rosato A. Frasson C. (2011). The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 (4), 759–772. 10.1016/j.cell.2011.09.048 22078877 Cox A. G. Tsomides A. Yimlamai D. Hwang K. L. Miesfeld J. Galli G. G. (2018). Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J. 37 (22), e100294. 10.15252/embj.2018100294 30348863 Cunningham R. Hansen C. G. (2022). The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin. Sci. 136 (3), 197–222. 10.1042/CS20201474 35119068 Dehelean C. A. Marcovici I. Soica C. Mioc M. Coricovac D. Iurciuc S. (2021). Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy. Molecules 26 (4), 1109. 10.3390/molecules26041109 33669817 Deng L. Zou J. Su Y. Wang M. Zhao L. (2022). Resveratrol inhibits TGF-β1-induced EMT in gastric cancer cells through Hippo-YAP signaling pathway. Clin. Transl. Oncol. 24 (11), 2210–2221. 10.1007/s12094-022-02882-z 35842894 Devaraji M. Thanikachalam P. V. (2025). Phytoconstituents as emerging therapeutics for breast cancer: mechanistic insights and clinical implications. Cancer Pathog. Ther. 3 (5), 364–382. 10.1016/j.cpt.2025.02.006 40923028 Díaz-Martín J. López-García M. Á. Romero-Pérez L. Atienza-Amores M. R. Pecero M. L. Castilla M. Á. (2015). Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr. Relat. Cancer 22 (3), 443–454. 10.1530/ERC-14-0456 25870251 Farahmand L. Darvishi B. Majidzadeh-A K. Madjid Ansari A. (2017). Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/β-catenin signalling pathways. Cell Prolif. 50 (1), e12299. 10.1111/cpr.12299 27669681 Farooqi A. A. Pinheiro M. Granja A. Farabegoli F. Reis S. Attar R. (2020). EGCG mediated targeting of deregulated signaling pathways and non-coding RNAs in different cancers: focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways. Cancers 12 (4), 951. 10.3390/cancers12040951 32290543 Fedele M. Sgarra R. Battista S. Cerchia L. Manfioletti G. (2022). The epithelial-mesenchymal transition at the crossroads between metabolism and tumor progression. Int. J. Mol. Sci. 23 (2), 800. 10.3390/ijms23020800 35054987 Franklin J. M. Wu Z. Guan K. L. (2023). Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat. Rev. Cancer 23 (8), 512–525. 10.1038/s41568-023-00579-1 37308716 Fu M. Hu Y. Lan T. Guan K. L. Luo T. Luo M. (2022). The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct. Target Ther. 7 (1), 376. 10.1038/s41392-022-01191-9 36347846 Furth N. Aylon Y. (2017). The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 24 (9), 1488–1501. 10.1038/cdd.2017.99 28644436 Gao Y. Zhao J. Zu Y. Fu Y. Liang L. Luo M. (2012). Antioxidant properties, superoxide dismutase and glutathione reductase activities in HepG2 cells with a fungal endophyte producing apigenin from pigeon pea [Cajanus cajan (L.) Millsp.]. Food Res. Int. 49 (1), 147–152. 10.1016/j.foodres.2012.08.001 Gao Y. Shi Q. Xu S. Du C. Liang L. Wu K. (2014). Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells. Int. J. Mol. Sci. 15 (9), 15173–15187. 10.3390/ijms150915173 25170806 Ghaboura N. (2025). Unraveling the Hippo pathway: YAP/TAZ as central players in cancer metastasis and drug resistance. EXCLI J. 24, 612–637. 10.17179/excli2025-8351 40630468 Golonko A. Olichwier A. J. Szklaruk A. Paszko A. Świsłocka R. Szczerbiński Ł. (2024). Apigenin's modulation of doxorubicin efficacy in breast cancer. Molecules 29 (11), 2603. 10.3390/molecules29112603 38893482 Guo Z. Han S. (2023). Targeting cancer stem cell plasticity in triple-negative breast cancer. Explor Target Antitumor Ther. 4 (6), 1165–1181. 10.37349/etat.2023.00190 38213533 Guo J. Wu Y. Yang L. Du J. Gong K. Chen W. (2017). Repression of YAP by NCTD disrupts NSCLC progression. Oncotarget 8 (2), 2307–2319. 10.18632/oncotarget.13668 27903989 Guo S. Bai X. Shi S. Deng Y. Kang X. An H. (2021). TMEM16A, a homoharringtonine receptor, as a potential endogenic target for lung cancer treatment. Int. J. Mol. Sci. 22 (20), 10930. 10.3390/ijms222010930 34681590 Guo P. Wan S. Guan K. L. (2025). The Hippo pathway: organ size control and beyond. Pharmacol. Rev. 77 (2), 100031. 10.1016/j.pharmr.2024.100031 40148032 Han Y. Guo W. Ren T. Huang Y. Wang S. Liu K. (2019a). Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. Cancer Lett. 440–441, 116–125. 10.1016/j.canlet.2018.10.011 30343113 Han Y. Jo H. Cho J. H. Dhanasekaran D. N. Song Y. S. (2019b). Resveratrol as a tumor-suppressive nutraceutical modulating tumor microenvironment and malignant behaviors of cancer. Int. J. Mol. Sci. 20 (4), 925. 10.3390/ijms20040925 30791624 Harvey K. Tapon N. (2007). The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat. Rev. Cancer 7 (3), 182–191. 10.1038/nrc2070 17318211 Harvey K. F. Zhang X. Thomas D. M. (2013). The Hippo pathway and human cancer. Nat. Rev. Cancer 13 (4), 246–257. 10.1038/nrc3458 23467301 Hillen H. Candi A. Vanderhoydonck B. Kowalczyk W. Sansores-Garcia L. Kesikiadou E. C. (2024). A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models. Mol. Cancer Ther. 23 (1), 3–13. 10.1158/1535-7163.MCT-22-0681 37748190 Hołota M. Posmyk M. M. (2025). Nature-inspired strategies in cancer management: the potential of plant extracts in modulating tumour biology. Int. J. Mol. Sci. 26 (14), 6894. 10.3390/ijms26146894 40725141 Huang Z. Zhou J. K. Wang K. Chen H. Qin S. Liu J. (2020). PDLIM1 inhibits tumor metastasis through activating Hippo signaling in hepatocellular carcinoma. Hepatology 71 (5), 1643–1659. 10.1002/hep.30930 31509262 Ichikawa M. K. Endo K. Itoh Y. Osada A. H. Kimura Y. Ueki K. (2022). Ets family proteins regulate the EMT transcription factors snail and ZEB in cancer cells. FEBS Open Bio 12 (7), 1353–1364. 10.1002/2211-5463.13415 35451213 Joo J. S. Cho S. Y. Rou W. S. Kim J. S. Kang S. H. Lee E. S. (2020). TEAD2 as a novel prognostic factor for hepatocellular carcinoma. Oncol. Rep. 43 (6), 1785–1796. 10.3892/or.2020.7578 32323824 Kanlaya R. Khamchun S. Kapincharanon C. Thongboonkerd V. (2016). Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells. Sci. Rep. 6, 30233. 10.1038/srep30233 27452398 Kantarjian H. M. O'Brien S. Cortes J. (2013). Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin. Lymphoma Myeloma Leuk. 13 (5), 530–533. 10.1016/j.clml.2013.03.017 23790799 Khatua S. Nandi S. Nag A. Sen S. Chakraborty N. Naskar A. (2024). Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications. Eur. J. Med. Res. 29 (1), 269. 10.1186/s40001-024-01856-x 38704602 Kim J. M. Kang D. W. Long L. Z. Huang S. M. Yeo M. K. Yi E. S. (2011). Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma. Hum. Pathol. 42 (3), 315–323. 10.1016/j.humpath.2010.08.003 21190720 Kim J. H. Kim Y. H. Song G. Y. Kim D. E. Jeong Y. J. Liu K. H. (2014). Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of β-catenin degradation. Food Chem. Toxicol. 67, 87–95. 10.1016/j.fct.2014.02.019 24566423 Kim T. Yang S. J. Hwang D. Song J. Kim M. Kyum Kim S. (2015). A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat. Commun. 6, 10186. 10.1038/ncomms10186 26671411 Kim S. H. Ryu H. G. Lee J. Shin J. Harikishore A. Jung H. Y. (2015). Ursolic acid exerts anti-cancer activity by suppressing vaccinia-related kinase 1-mediated damage repair in lung cancer cells. Sci. Rep. 5, 14570. 10.1038/srep14570 26412148 Kim W. Khan S. K. Gvozdenovic-Jeremic J. Kim Y. Dahlman J. Kim H. (2017). Hippo signaling interactions with Wnt/β-catenin and notch signaling repress liver tumorigenesis. J. Clin. Invest. 127 (1), 137–152. 10.1172/JCI88486 27869648 Kim S. H. Jin H. Meng R. Y. Kim D. Y. Liu Y. C. Chai O. H. (2019). Activating Hippo pathway via Rassf1 by Ursolic acid suppresses the tumorigenesis of gastric cancer. Int. J. Mol. Sci. 20 (19), 4709. 10.3390/ijms20194709 31547587 Kim I. Park T. Noh J. Y. Kim W. (2023). Emerging role of Hippo pathway in the regulation of hematopoiesis. BMB Rep. 56 (8), 417–425. 10.5483/BMBRep.2023-0094 37574808 Koo J. H. Guan K. L. (2018). Interplay between YAP/TAZ and metabolism. Cell Metab. 28 (2), 196–206. 10.1016/j.cmet.2018.07.010 30089241 Kunnumakkara A. B. Anand P. Aggarwal B. B. (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269 (2), 199–225. 10.1016/j.canlet.2008.03.009 18479807 Kuser-Abali G. Alptekin A. Lewis M. Garraway I. P. Cinar B. (2015). YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat. Commun. 6, 8126. 10.1038/ncomms9126 28230103 Labibi B. Bashkurov M. Wrana J. L. Attisano L. (2020). Modeling the control of TGF-β/Smad nuclear accumulation by the Hippo pathway effectors, Taz/Yap. iScience 23 (8), 101416. 10.1016/j.isci.2020.101416 32798968 Lee I. G. Lee J. Hong S. H. Seo Y. J. (2023). Apigenin's therapeutic potential against viral infection. Front. Biosci. 28 (10), 237. 10.31083/j.fbl2810237 37919082 Li F. L. Guan K. L. (2022). The two sides of Hippo pathway in cancer. Semin. Cancer Biol. 85, 33–42. 10.1016/j.semcancer.2021.07.006 34265423 Li Y. W. Xu J. Zhu G. Y. Huang Z. J. Lu Y. Li X. Q. (2018). Apigenin suppresses the stem cell-like properties of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Cell Death Discov. 4, 105. 10.1038/s41420-018-0124-8 30479839 Li A. Gu K. Wang Q. Chen X. Fu X. Wang Y. (2018). Epigallocatechin-3-gallate affects the proliferation, apoptosis, migration and invasion of tongue squamous cell carcinoma through the hippo-TAZ signaling pathway. Int. J. Mol. Med. 42 (5), 2615–2627. 10.3892/ijmm.2018.3818 30106116 Liang Y. C. Zhong Q. Ma R. H. Ni Z. J. Thakur K. Khan M. R. (2022). Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress. J. Funct. Foods 94, 105116. 10.1016/j.jff.2022.105116 Lin K. C. Moroishi T. Meng Z. Jeong H. S. Plouffe S. W. Sekido Y. (2017). Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat. Cell Biol. 19 (8), 996–1002. 10.1038/ncb3581 28752853 Lu Z. Liu L. Zhao S. Zhao J. Li S. Li M. (2023). Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice. Sci. Rep. 13 (1), 7996. 10.1038/s41598-023-34654-2 37198205 Maashi M. S. Al-Mualm M. Al-Awsi G. R. L. Opulencia M. J. C. Al-Gazally M. E. Abdullaev B. (2022). Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway. Mol. Biol. Rep. 49 (9), 8777–8784. 10.1007/s11033-022-07727-0 35804214 Meng Z. Moroishi T. Mottier-Pavie V. Plouffe S. W. Hansen C. G. Hong A. W. (2015). MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun. 6, 8357. 10.1038/ncomms9357 26437443 Meng X. Zhou J. Zhao C. N. Gan R. Y. Li H. B. (2020). Health benefits and molecular mechanisms of resveratrol: a narrative review. Foods 9 (3), 340. 10.3390/foods9030340 32183376 Misra J. R. Irvine K. D. (2018). The Hippo signaling network and its biological functions. Annu. Rev. Genet. 52, 65–87. 10.1146/annurev-genet-120417-031621 30183404 Mohajan S. Jaiswal P. K. Vatanmakarian M. Yousefi H. Sankaralingam S. Alahari S. K. (2021). Hippo pathway: regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett. 507, 112–123. 10.1016/j.canlet.2021.03.006 33737002 Mohammadi S. Arefnezhad R. Danaii S. Yousefi M. (2020). New insights into the core Hippo signaling and biological macromolecules interactions in the biology of solid tumors. Biofactors 46 (4), 514–530. 10.1002/biof.1634 32445262 Mokhtari R. B. Ashayeri N. Baghaie L. Sambi M. Satari K. Baluch N. (2023). The Hippo pathway effectors YAP/TAZ-TEAD oncoproteins as emerging therapeutic targets in the Tumor microenvironment. Cancers 15 (13), 3468. 10.3390/cancers15133468 37444578 Moloudizargari M. Asghari M. H. Nabavi S. F. Gulei D. Berindan-Neagoe I. Bishayee A. (2022). Targeting Hippo signaling pathway by phytochemicals in cancer therapy. Semin. Cancer Biol. 80, 183–194. 10.1016/j.semcancer.2020.05.005 32428716 Moroishi T. Hayashi T. Pan W. W. Fujita Y. Holt M. V. Qin J. (2016). The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell 167 (6), 1525–1539.e17. 10.1016/j.cell.2016.11.005 27912060 Moya I. M. Castaldo S. A. Van den Mooter L. Soheily S. Sansores-Garcia L. Jacobs J. (2019). Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science 366 (6468), 1029–1034. 10.1126/science.aaw9886 31754005 Nguyen H. N. Ullevig S. L. Short J. D. Wang L. Ahn Y. J. Asmis R. (2021). Ursolic acid and related analogues: triterpenoids with broad health benefits. Antioxidants 10 (8), 1161. 10.3390/antiox10081161 34439409 Nicolaescu O. E. Belu I. Mocanu A. G. Manda V. C. Rău G. Pîrvu A. S. (2025). Cyclodextrins: enhancing drug delivery, solubility and bioavailability for modern therapeutics. Pharmaceutics 17 (3), 288. 10.3390/pharmaceutics17030288 40142952 Noland C. L. Gierke S. Schnier P. D. Murray J. Sandoval W. N. Sagolla M. (2016). Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling. Structure 24 (1), 179–186. 10.1016/j.str.2015.11.005 26724994 Ordaz-Ramos A. Tellez-Jimenez O. Vazquez-Santillan K. (2023). Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications. Front. Cell Dev. Biol. 11, 1221175. 10.3389/fcell.2023.1221175 37492224 Pandey P. Khan F. Upadhyay T. K. (2023). Deciphering the modulatory role of apigenin targeting oncogenic pathways in human cancers. Chem. Biol. Drug Des. 101 (6), 1446–1458. 10.1111/cbdd.14206 36746671 Parker J. M. Zhao L. Mayberry T. G. Cowan B. C. Wakefield M. R. Fang Y. (2025). From spice to survival: the emerging role of curcumin in cancer immunotherapy. Cancers 17 (15), 2491. 10.3390/cancers17152491 40805190 Patterson M. R. Cogan J. A. Cassidy R. Theobald D. A. Wang M. Scarth J. A. (2024). The Hippo pathway transcription factors YAP and TAZ play HPV-type dependent roles in cervical cancer. Nat. Commun. 15 (1), 5809. 10.1038/s41467-024-49965-9 38987584 Pei T. Li Y. Wang J. Wang H. Liang Y. Shi H. (2015). YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget 6 (19), 17206–17220. 10.18632/oncotarget.4043 26015398 Peñaherrera-Pazmiño A. B. Criollo M. Gonzalez-Pastor R. (2025). Phytochemical nanoencapsulation and microfluidics drive gene and tumor microenvironment modulation. Front. Pharmacol. 16, 1694752. 10.3389/fphar.2025.1694752 41089841 Peng L. Jiang D. (2018). Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition. PLoS One 13 (10), e0205918. 10.1371/journal.pone.0205918 30356255 Perra A. Kowalik M. A. Ghiso E. Ledda-Columbano G. M. Di Tommaso L. Angioni M. M. (2014). YAP activation is an early event and a potential therapeutic target in liver cancer development. J. Hepatol. 61 (5), 1088–1096. 10.1016/j.jhep.2014.06.033 25010260 Piccolo S. Panciera T. Contessotto P. Cordenonsi M. (2023). YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat. Cancer 4 (1), 9–26. 10.1038/s43018-022-00473-z 36564601 Plouffe S. W. Hong A. W. Guan K. L. (2015). Disease implications of the Hippo/YAP pathway. Trends Mol. Med. 21 (4), 212–222. 10.1016/j.molmed.2015.01.003 25702974 Plouffe S. W. Meng Z. Lin K. C. Lin B. Hong A. W. Chun J. V. (2016). Characterization of Hippo pathway components by gene inactivation. Mol. Cell 64 (5), 993–1008. 10.1016/j.molcel.2016.10.034 27912098 Plouffe S. W. Lin K. C. Moore J. L. Tan F. E. Ma S. Ye Z. (2018). The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J. Biol. Chem. 293 (28), 11230–11240. 10.1074/jbc.RA118.002715 29802201 Prasad S. Yadav V. R. Sung B. Gupta S. C. Tyagi A. K. Aggarwal B. B. (2016). Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. Oncotarget 7 (11), 13182–13196. 10.18632/oncotarget.7537 26909608 Praskova M. Xia F. Avruch J. (2008). MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr. Biol. 18 (5), 311–321. 10.1016/j.cub.2008.02.006 18328708 Qi S. Zhu Y. Liu X. Li P. Wang Y. Zeng Y. (2022). WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Mol. Cell 82 (10), 1850–1864.e7. 10.1016/j.molcel.2022.03.027 35429439 Qin X. Luo H. Deng Y. Yao X. Zhang J. He B. (2022). Resveratrol inhibits proliferation and induces apoptosis via the Hippo/YAP pathway in human colon cancer cells. Biochem. Biophys. Res. Commun. 636 (Pt 1), 197–204. 10.1016/j.bbrc.2022.10.077 36335870 Quintás-Cardama A. Kantarjian H. Cortes J. (2009). Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115 (23), 5382–5393. 10.1002/cncr.24601 19739234 Rai A. Bhatia R. Singh R. K. (2025). Nature-Inspired anticancer agents: the synergy of phytochemicals and synthetic analogs (2019-2024). Chem. Biodivers. 22, e202500162. 10.1002/cbdv.202500162 40213994 Reggiani F. Gobbi G. Ciarrocchi A. Sancisi V. (2021). YAP and TAZ are not identical twins. Trends Biochem. Sci. 46 (2), 154–168. 10.1016/j.tibs.2020.08.012 32981815 Rosenbluh J. Nijhawan D. Cox A. G. Li X. Neal J. T. Schafer E. J. (2012). β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151 (7), 1457–1473. 10.1016/j.cell.2012.11.026 23245941 Salehi B. Venditti A. Sharifi-Rad M. Kręgiel D. Sharifi-Rad J. Durazzo A. (2019). The therapeutic potential of apigenin. Int. J. Mol. Sci. 20 (6), 1305. 10.3390/ijms20061305 30875872 Senga S. S. Grose R. P. (2021). Hallmarks of cancer-the new testament. Open Biol. 11 (1), 200358. 10.1098/rsob.200358 33465324 Shen T. Li Y. Zhu S. Yu J. Zhang B. Chen X. (2020). YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression. J. Exp. Clin. Cancer Res. 39 (1), 36. 10.1186/s13046-020-1542-z 32066485 Shin Y. S. Kang S. U. Park J. K. Kim Y. E. Kim Y. S. Baek S. J. (2016). Anti-cancer effect of (-)-epigallocatechin-3-gallate (EGCG) in head and neck cancer through repression of transactivation and enhanced degradation of β-catenin. Phytomedicine 23 (12), 1344–1355. 10.1016/j.phymed.2016.07.005 27765354 Shreberk-Shaked M. Oren M. (2019). New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities? Mol. Oncol. 13 (6), 1335–1341. 10.1002/1878-0261.12498 31050214 Sohel M. Aktar S. Biswas P. Amin M. A. Hossain M. A. Ahmed N. (2023). Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: a comprehensive review. Cancer Med. 12 (13), 14556–14583. 10.1002/cam4.5984 37132286 Song H. Lu T. Han D. Zhang J. Gan L. Xu C. (2024). YAP1 inhibition induces phenotype switching of cancer-associated fibroblasts to tumor suppressive in prostate cancer. Cancer Res. 84 (22), 3728–3742. 10.1158/0008-5472.CAN-24-0932 39137404 Suto H. (2024). Role of the Hippo-YAP/TAZ pathway in epithelioid Hemangioendothelioma and its potential as a therapeutic target. Anticancer Res. 44 (10), 4147–4153. 10.21873/anticanres.17245 39348982 Swerdlow S. H. Campo E. Pileri S. A. Harris N. L. Stein H. Siebert R. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127 (20), 2375–2390. 10.1182/blood-2016-01-643569 26980727 Talib W. H. Awajan D. Alqudah A. Alsawwaf R. Althunibat R. Abu AlRoos M. (2024). Targeting cancer hallmarks with Epigallocatechin gallate (EGCG): mechanistic basis and therapeutic targets. Molecules 29 (6), 1373. 10.3390/molecules29061373 38543009 Talukdar P. D. Pramanik K. Gatti P. Mukherjee P. Ghosh D. Roy H. (2025). Precise targeting of transcriptional co-activators YAP/TAZ annihilates chemoresistant brCSCs by alteration of their mitochondrial homeostasis. Signal Transduct. Target Ther. 10 (1), 61. 10.1038/s41392-025-02133-x 39979255 Tang J. F. Li G. L. Zhang T. Du Y. M. Huang S. Y. Ran J. H. (2021). Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2/M cell cycle arrest. Arch. Biochem. Biophys. 700, 108774. 10.1016/j.abb.2021.108774 33548212 van Soldt B. J. Cardoso W. V. (2020). Hippo-Yap/Taz signaling: complex network interactions and impact in epithelial cell behavior. Wiley Interdiscip. Rev. Dev. Biol. 9 (3), e371. 10.1002/wdev.371 31828974 Varoni E. M. Lo Faro A. F. Sharifi-Rad J. Iriti M. (2016). Anticancer molecular mechanisms of resveratrol. Front. Nutr. 3, 8. 10.3389/fnut.2016.00008 27148534 Wang W. Zhao C. Jou D. Lü J. Zhang C. Lin L. (2013). Ursolic acid inhibits the growth of colon cancer-initiating cells by targeting STAT3. Anticancer Res. 33 (10), 4279–4284.24122993 Wang Y. Pan P. Wang Z. Zhang Y. Xie P. Geng D. (2017). β-catenin-mediated YAP signaling promotes human glioma growth. J. Exp. Clin. Cancer Res. 36 (1), 136. 10.1186/s13046-017-0606-1 28962630 Wang Y. Xu X. Maglic D. Dill M. T. Mojumdar K. Ng P. K. (2018). Comprehensive molecular characterization of the hippo signaling pathway in cancer. Cell Rep. 25 (5), 1304–1317.e5. 10.1016/j.celrep.2018.10.001 30380420 Wang H. Wang R. Huang D. Li S. Gao B. Kang Z. (2021). Homoharringtonine exerts anti-tumor effects in hepatocellular carcinoma through activation of the Hippo pathway. Front. Pharmacol. 12, 592071. 10.3389/fphar.2021.592071 33716735 Wang J. Huang P. Pan X. Xia C. Zhang H. Zhao H. (2023). Resveratrol reverses TGF-β1-mediated invasion and metastasis of breast cancer cells via the SIRT3/AMPK/autophagy signal axis. Phytother. Res. 37 (1), 211–230. 10.1002/ptr.7608 36086852 Wang Y. Wu N. Li J. Zhou D. Liang J. Cao Q. (2024). YAP1 regulates the YAP1/AR/PSA axis through autophagy in castration-resistant prostate cancer and mediates T-Cell immune and inflammatory cytokine infiltration. Biomedicines 12 (3), 661. 10.3390/biomedicines12030661 38540274 Weiler S. M. E. Lutz T. Bissinger M. Sticht C. Knaub M. Gretz N. (2020). TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Cancer Lett. 473, 164–175. 10.1016/j.canlet.2019.12.044 31904487 Xu G. Chen J. Wang G. Xiao J. Zhang N. Chen Y. (2020). Resveratrol inhibits the tumorigenesis of follicular thyroid cancer via ST6GAL2-Regulated activation of the hippo signaling pathway. Mol. Ther. Oncolytics 16, 124–133. 10.1016/j.omto.2019.12.010 32055676 Xuan W. Song D. Hou J. Meng X. (2025). Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease. Front. Pharmacol. 16, 1505117. 10.3389/fphar.2025.1505117 39917623 Yamaguchi H. Taouk G. M. (2020). A potential role of YAP/TAZ in the interplay between metastasis and metabolic alterations. Front. Oncol. 10, 928. 10.3389/fonc.2020.00928 32596154 Yang D. Zhang N. Li M. Hong T. Meng W. Ouyang T. (2021). The Hippo signaling pathway: the trader of tumor microenvironment. Front. Oncol. 11, 772134. 10.3389/fonc.2021.772134 34858852 Yang L. Wang B. Jiao X. Zhou C. Chen S. Gao X. (2021). TAZ maintains telomere length in TNBC cells by mediating Rad51C expression. Breast Cancer Res. 23 (1), 89. 10.1186/s13058-021-01466-z 34488828 Yang J. Wu X. Wang J. Guo X. Chen J. Yang X. (2023). Feedforward loop between IMP1 and YAP/TAZ promotes tumorigenesis and malignant progression in glioblastoma. Cancer Sci. 114 (5), 2053–2062. 10.1111/cas.15636 36308276 Yang P. Li Y. Hou J. Wu D. Zeng X. Zeng Z. (2024). Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer. J. Biol. Chem. 300 (6), 107309. 10.1016/j.jbc.2024.107309 38657867 Yip H. Y. K. Papa A. (2021). Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments. Cells 10 (3), 659. 10.3390/cells10030659 33809714 You W. Di A. Zhang L. Zhao G. (2022). Effects of wogonin on the growth and metastasis of colon cancer through the Hippo signaling pathway. Bioengineered 13 (2), 2586–2597. 10.1080/21655979.2021.2019173 35037825 Yu F. X. Guan K. L. (2013). The Hippo pathway: regulators and regulations. Genes Dev. 27 (4), 355–371. 10.1101/gad.210773.112 23431053 Yu M. Wang J. Zhang X. Zhang H. Li C. Li J. (2025). The mechanism of YAP/TAZ transactivation and dual targeting for cancer therapy. Nat. Commun. 16 (1), 3855. 10.1038/s41467-025-59309-w 40274828 Zafar S. Khan K. Hafeez A. Irfan M. Armaghan M. Rahman A. U. (2022). Ursolic acid: a natural modulator of signaling networks in different cancers. Cancer Cell Int. 22 (1), 399. 10.1186/s12935-022-02804-7 36496432 Zanconato F. Forcato M. Battilana G. Azzolin L. Quaranta E. Bodega B. (2015). Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 17 (9), 1218–1227. 10.1038/ncb3216 26258633 Zeng J. Xie H. Zhang Z. L. Li Z. X. Shi L. Wu K. Y. (2022). Apigenin regulates the migration, invasion, and autophagy of hepatocellular carcinoma cells by downregulating YAP. Neoplasma 69 (2), 292–302. 10.4149/neo_2021_210615N798 35014535 Zhang Y. H. Li B. Shen L. Shen Y. Chen X. D. (2013). The role and clinical significance of YES-associated protein 1 in human osteosarcoma. Int. J. Immunopathol. Pharmacol. 26 (1), 157–167. 10.1177/039463201302600115 23527718 Zhang L. Yang S. Chen X. Stauffer S. Yu F. Lele S. M. (2015). The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol. Cell Biol. 35 (8), 1350–1362. 10.1128/MCB.00102-15 25645929 Zhang H. Geng D. Gao J. Qi Y. Shi Y. Wang Y. (2016). Expression and significance of Hippo/YAP signaling in glioma progression. Tumour Biol. 37, 15665–15676. 10.1007/s13277-016-5318-1 27718125 Zhang X. Zhao H. Li Y. Xia D. Yang L. Ma Y. (2018). The role of YAP/TAZ activity in cancer metabolic reprogramming. Mol. Cancer 17 (1), 134. 10.1186/s12943-018-0882-1 30176928 Zhang A. Aslam H. Sharma N. Warmflash A. Fakhouri W. D. (2021). Conservation of epithelial-to-mesenchymal transition process in neural crest cells and metastatic cancer. Cells Tissues Organs 210 (3), 151–172. 10.1159/000516466 34218225 Zhang C. Liao Y. Li T. Zhong H. Shan L. Yu P. (2024). Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo. Toxicol. Res. 13 (1), tfae011. 10.1093/toxres/tfae011 38283821 Zhao J. Leng P. Xu W. Sun J. L. Ni B. B. Liu G. W. (2021). Investigating the multitarget pharmacological mechanism of ursolic acid acting on Colon cancer: a network pharmacology approach. Evid. Based Complement. Altern. Med. 2021, 9980949. 10.1155/2021/9980949 34194533 Zheng Y. Wang W. Liu B. Deng H. Uster E. Pan D. (2015). Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the Hippo kinase Cascade. Dev. Cell 34 (6), 642–655. 10.1016/j.devcel.2015.08.014 26364751 Zheng Y. Yang X. Tan J. Tian R. Shen P. Cai W. (2021). Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ. Environ. Toxicol. 36 (6), 1135–1142. 10.1002/tox.23112 33539684 Zhou X. Su J. Feng S. Wang L. Yin X. Yan J. (2016). Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells. Oncotarget 7 (48), 79076–79088. 10.18632/oncotarget.12596 27738325 Zhou Y. Wang Y. Zhou W. Chen T. Wu Q. Chutturghoon V. K. (2019). YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int. 19, 179. 10.1186/s12935-019-0898-7 31337986 Zhu J. Zhao B. Xiong P. Wang C. Zhang J. Tian X. (2018). Curcumin induces autophagy via inhibition of yes-associated protein (YAP) in human Colon cancer cells. Med. Sci. Monit. 24, 7035–7042. 10.12659/MSM.910650 30281585